ClinicalTrials.gg
RecruitingNCT06210022Updated Jun 24, 2024

Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy

An observational study in Epilepsy and Focal Epilepsy, sponsored by IRCCS San Raffaele. Recruiting at 1 site in Italy. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-06-24.

Primary conditionEpilepsies, PartialRegistry: EpilepsyReclassifiedWhy we changed it
Registry
Epilepsy — the first condition term the registry derived for this study.
ClinicalTrials.gg
Epilepsies, Partial
Why
  1. The study's listed conditions name Epilepsies, Partial, a narrower term within Epilepsy.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by IRCCS San Raffaele · Observational

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
130
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 18 studies in Epilepsies, Partial with a site in Italy — 4 open to participants now, 6 under way, 2 of them phase 3. Epilepsies, Partial · Italy.

Started
2024
with 3 others
Observational
Only one
of the 18
Registered
15th of 18
by date
Lead sponsor
1 of 18
IRCCS San Raffaele

Among the 18 studies in Epilepsies, Partial with a site in Italy, this one is one of 4 that started in 2024, is the only observational one, and was the 15th registered.

Epilepsies, Partial

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

Browse Epilepsies, Partial studies →

Open to participants now

4 of the 18 studies in Epilepsies, Partial with a site in Italy are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Epilepsies, Partial with a site in Italy, or all of them as a file.
02

Study summary

This is a national monocentric (San Raffaele Hospital - OSR, Via Olgettina, 60, 20132 Milan, Italy) observational low-risk-intervention study, prospective and multiparametric (clinical, EEG, neuropsychological evaluations) study.

Patients with a diagnosis of DRE and DSE will be screened to evaluate their eligibility. They will undergo clinical and cognitive assessments in addition to 32channel EEG at baseline (T0). DRE patients will also undergo clinical and cognitive assessments, and 32-channel EEG at 6 months (T1), and 12 months (T2). Patients newly diagnosed with focal cryptogenic epilepsy (NDE) will undergo clinical and cognitive assessments, and 32-channel EEG at baseline (T0), at 6 months (T1), and 12 months (T2).

High-definition EEG will be performed to investigate patterns of cortical sources and functional connectivity alteration specific to DRE and DSE and to explore their prognostic value. Longitudinal EEGs will be acquired to explore the evolution of EEG patterns.

Cognitive evaluation will be performed by an experienced neuropsychologist. At baseline, DRE, DSE, and NDE patients will undergo a screening and a comprehensive cognitive battery in order to define performance differences among groups. The DRE and NDE group only will perform the same neuropsychological assessment at month 6 and 12 for monitoring the potential progression of cognitive and/or behavioural disturbances in these patients.

Read the detailed description

At the study entry (T0) DSE, DRE, and NDE will undergo cognitive evaluations (investigating the main cognitive domains), neurological examinations, and 32channel EEG. DRE and NDE patients will undergo the same clinical, cognitive and 32-channel EEG evaluations at T1 (6 months) and T2 (12 months). DSE patients will be tested only at baseline and they will not undergo longitudinal evaluations.

ASM therapy and seizure frequency will be recorded for DRE and NDE patients in a dedicated database at T0, T1 and T2 High-density EEGs, with a duration of 20 minutes, will be acquired in resting awake conditions on a computer-based system (Micromed System PLUS, Micromed S.p.A., Mogliano Veneto, Italy) from 32 surface electrodes, placed on an EEG cap according to the international 10/20 system, with linked-ear or mesial prefrontal reference. Vigilance will be continuously monitored in order to avoid drowsiness. The quality of sleep during the night previous to the exam will be investigated by the recording technician. Standard clinical procedures will be implemented in the acquisition protocol.

Cognitive evaluations will be performed by an experienced neuropsychologist. The following domains will be assessed: global cognition, memory, language, attention, executive functions, visuospatial abilities, mood and behavior. Moreover, for the assessment of quality of life, the 12-item Short Form Survey (SF-12) will be administered to DSE patients at baseline, and to NDE patients and DRE at baseline and at the follow-up.

Clinical and cognitive data will be exported and analyzed through SPSS and/or R software afterwards. All demographic, personal and clinical information will be codified.

EEG will be stored in a digital archive and on CDs, and then uploaded on dedicated PCs and Linux stations in order to perform the analyses

03

Conditions studied

  • Epilepsy
  • Focal Epilepsy

Browse trials for

Keywords

  • epilepsy
  • focal cryptogenic epilepsy
  • drug resistant epilepsy
04

In context

Epilepsies, Partial Reclassified

243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.

This study's planned enrollment of 130 is close to the median of 130 across 47 observational studies indexed under Epilepsies, Partial.

Browse Epilepsies, Partial studies →

Lead sponsor

IRCCS San Raffaele is the lead sponsor of 458 studies on the registry; 237 are open to participants now.

Compared within Epilepsies, Partial, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Epilepsy. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with diagnosis of DRE and DSE will be recruited among patients who are regularly followed at our Epilepsy Outpatients Service (OSR). The diagnosis of DRE and DSE focal cryptogenic epilepsy will be based on the most recent sets of criteria of different types of epilepsy.

A small group of NDE patients will be also enrolled.

Eligibility criteria

Inclusion Criteria:

  • Inclusion criteria for all study subjects:

    • monolingual native Italian speakers;
    • age between 18-60 years;
    • normal or corrected-to-normal visual acuity;
    • oral and written to study participation.
    • if assuming psychotropic drugs (i.e., benzodiazepines, antipsychotics, antidepressants), they should be at stable dosage for more than 4 weeks.
  • Inclusion criteria for DRE patients:

    • diagnosis of focal cryptogenic epilepsy;
    • previous failure of at least 2 anti-seizure medication (ASM at adequate dose;
    • at least 3 seizures in the last 2 months; • available brain MRI (\<5 years).
  • Inclusion criteria for DSE patients:

    • diagnosis of focal cryptogenic epilepsy;
    • seizure control obtained after not more than 2 ASM;
    • seizure freedom for at least 6 months;
    • available brain MRI (\<5 years).
  • Inclusion criteria for NDE patients:

    • new diagnosis of focal cryptogenic epilepsy (\<3 months)
    • not more than 1 ASM tested
    • available brain MRI (\<3 months)

Exclusion Criteria:

  • Age> 60 years;
  • Documented developmental delay;
  • Evidence of focal abnormalities at neuroimaging (except of hippocampal sclerosis);
  • Neurological degenerative conditions;
  • history of other systemic (including systemic neoplasms in the last 3 years and abnormal hepatorenal functions), neurologic, psychiatric diseases, head injury, cardiovascular events, and cerebrovascular alterations;
  • alcohol and/or psychotropic drugs abuse
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

06

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
130 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • 130

    Patients with diagnosis of DRE and DSE will be recruited among patients who are regularly followed at our Epilepsy Outpatients Service (OSR). The diagnosis of DRE and DSE focal cryptogenic epilepsy will be based on the most recent sets of criteria of different types of epilepsy. A small group of NDE patients will be also enrolled A population of 30 focal cryptogenic epilepsy patients diagnosed with DRE (drug resistant epilepsy) A population of 90 focal cryptogenic epilepsy patients diagnosed with DRE (drug sensitive epilepsy) 10 patients newly diagnosed for focal cryptogenic epilepsy (NDE) will be recruited too.

    Diagnostic Test: Neuropsychological Assessment

Interventions

  • Diagnostic testNeuropsychological Assessment

    Cognitive evaluation and clinical monitoring of seizure frequency

07

What researchers measure

Primary outcomes

  1. To evaluate the prevalence of cognitive impairment in a population of focal cryptogenic epilepsy patients, comparing subjects diagnosed with DRE (drug resistant epilepsy) and subjects diagnosed with DSE (drug sensitive epilepsy);

    At baseline, DRE and DSE patients will undergo a screening and comprehensive cognitive battery. We will adopt the following scales: EpiTrack screening battery; Rey Auditory Verbal Learning Test and with the Rey's figure recall; Token Test; Paced Auditory Serial Addition Test; Modified Card Sorting Test; Cognitive Estimation Task; Rey's figure copy, Beck Depression Inventory, Dimensional Apathy Scale, 12-item Short Form Survey. The suspect of cognitive impairment (CI) will be defined with EpiTrack screening battery (score \< 32 points indicates CI). This will be confirmed by the comprehensive battery (Level II): Impairment should be present on at least 2 tests. For each test, impairment will be demonstrated with performances below appropriate normative values. Since the classification for CI is not yet defined for epilepsy we will adopt the classification for Parkinson's disease which, as patients with epilepsy, mainly have disturbances in executive, attentive and memory functioning.

    Time frame: 2024-2027

  2. To monitor the evolution of cognitive performance in DRE patients over a period of one year;

    we evaluate the cognitive state of the patients with the measures and scales listed in "Outcome 1" at 12 months and compare the results to the baseline results.

    Time frame: 2024-2027

  3. To evaluate whether seizure frequency constitute the main determinant of cognitive impairment;

    We evaluate if patients who reduced the seizure frequence over a period of 12 months showed an improvement in the cognitive assesment, comparing baseline assesment and the follow up assesment at 12 months.

    Time frame: 2024-2027

  4. To explore EEG-markers of DRE and DSE

    High-density EEGs, with a duration of 20 minutes, will be acquired in resting awake conditions on a computer-based system (Micromed System PLUS, Micromed S.p.A., Mogliano Veneto, Italy) from 32 surface electrodes, placed on an EEG cap according to the international 10/20 system, with linked-ear or mesial prefrontal reference. Vigilance will be continuously monitored in order to avoid drowsiness. EEG will be performed to investigate patterns of cortical sources and functional connectivity alteration in the two different groups od DRE and DSE.

    Time frame: 2024-2027

  5. To evaluate the entity of cognitive impairment in a population of focal cryptogenic epilepsy patients, comparing subjects diagnosed with DRE (drug resistant epilepsy) and subjects diagnosed with DSE (drug sensitive epilepsy);

    To evaluate the entity of cognitive impairment in DSE with the measures and methods specified in "Outcome 1".

    Time frame: 2024-2027

  6. To evaluate whether ASM therapy constitute the main determinant of cognitive impairment;

    We evaluate if patients who reduced the number of ASMs medications over a period of 12 months showed an improvement in the cognitive assesment, comparing baseline assesment and the follow up assesment at 12 months.

    Time frame: 2024-2027

  7. To explore a possible relationship between EEG-markers of DRE and DSE and cognitive impairment

    To explore a possible relationship between EEG-markers of DRE and DSE found as specified in "Outcome 4" and cognitive impairment (evaluated as specified in "Outcome 1").

    Time frame: 2024-2027

Secondary outcomes

  1. To evaluate longitudinal evolution of cognitive performances in patients newly diagnosed with focal cryptogenic epilepsy (NDE)

    At baseline, NDE patients will undergo a screening and a comprehensive cognitive battery in order to define performance differences among groups. The NDE patients groups only will perform the same neuropsychological assessment at month 6 and 12 for monitoring the potential progression of cognitive and/or behavioral disturbances in these patients. We will use the same neuropsychological scales listed in "Outcome 1".

    Time frame: 2024-2027

  2. To evaluate longitudinal evolution of drug responsiveness in patients newly diagnosed with focal cryptogenic epilepsy (NDE)

    We evaluate if over a period of 6 and 12 months the patients of NDE groups have showed drug responsiveness, assessed as "reduction of number of seizure per month", compared to the baseline data.

    Time frame: 2024-2027

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2024 (actual). Primary completion is estimated for Mar 2027, 32 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 21, 2023
First posted
Jan 18, 2024
StartActual
Jun 20, 2024
Primary completionEst.
Mar 1, 2027
CompletionEst.
Mar 1, 2027
Last update
Jun 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06210022
Lead sponsor
IRCCS San Raffaele
Responsible party
Prof. Massimo Filippi (Professor Massimo Filippi, IRCCS San Raffaele) — Principal investigator
First posted
Jan 18, 2024
Start date
Jun 20, 2024
Primary completion
Mar 1, 2027 (estimated)
Completion
Mar 1, 2027 (estimated)
Last update
Jun 24, 2024

Study contacts

Anna Bellini, MD
Contact
bellini.anna@hsr.it
+390226432154
Davide Gusmeo Curti, MD
Contact
curti.davide@hsr.it
+390226432154

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion